Related Experiment Videos

Genetic forms of renal potassium and magnesium wasting

David G Warnock

The American Journal of Medicine

|March 15, 2002

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies.

Journal of inherited metabolic disease·2024

Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.

Journal of medical genetics·2023

Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry disease.

Human molecular genetics·2023

Risk Factors for Incident CKD in Black and White Americans: The REGARDS Study.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2023

Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study.

Molecular genetics and metabolism reports·2022

7th Update on Fabry Disease: Biomarkers, Progression and Treatment Opportunities in 2022.

Nephron·2022

See all related articles